Cardiol Therapeutics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CRDL.TO | HLS.TO | 2M7C.F | 1795.TW | RNA | SLDB | |
|---|---|---|---|---|---|---|
| Market cap | 174.98M | 131.47M | 2.87B | 44.76B | 148.48M | 699.11M |
| P/E (TTM) | — | — | 14.8 | 11.8 | — | — |
| Forward P/E | -4.4 | -43.2 | — | 7.1 | -1.5 | -3.8 |
| Price/book | 7.0 | 1.7 | 1.2 | 1.9 | 0.7 | 2.9 |
| Dividend yield | — | — | 3.42% | 1.61% | — | — |
| 1-year change | −1.96% | −21.44% | −28.57% | −42.88% | −41.15% | +54.69% |
| Today | −4.00% | +0.47% | +2.61% | +5.66% | −0.46% | +3.82% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 20 min.
Latest news
All CRDL.TO news ›Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds
/PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... - Proceeds strengthen balance sheet ahead of pivotal Phase III MAVERIC trial data readout in…
Fewer Relapses, So Why Expand This Heart Drug Trial? | David Elsley – Cardiol Therapeutics
Fewer Relapses, So Why Expand This Heart Drug Trial? | David Elsley - Cardiol Therapeutics the deep dive Fewer Relapses, So Why Expand This Heart Drug Trial? | David Elsley – Cardiol Therapeutics David Elsley, President and CEO of Cardiol…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- prnewswire.com1
- thedeepdive.ca1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.